. Author manuscript; available in PMC: 2022 Nov 29.

Published in final edited form as: J Am Acad Child Adolesc Psychiatry. 2019 May 23;59(3):350–361. doi: 10.1016/j.jaac.2019.05.015

TABLE 2.

Summary of Primary and Secondary Outcomes of the Randomized Controlled Trial With Adjunctive Citalopram Versus Placebo

					Between-Group Difference
Outcome	Baseline Randomization ^a		Week 8 of Trial ^b		Group by Week Interaction	At Week 8
	CTP	PBO	CTP	PBO	p	p
	% (SE) n	% (SE) n	% (SE) n	% (SE) n
CGI-I Response^c
Estimated	—	—	35 (10) 8	6 (4) 2	.006	.006
Observed	—	—	25 (10) 5	10 (7) 2	—	—
	Mean (SE) n	Mean (SE) n	Mean (SE)	Mean (SE)	p	p
CGI-S	4.0 (0.4) 23	4.3 (0.4) 26	3.1 (0.3)	3.9 (0.3)	.046	.085
CGAS	44.4 (0.2) 22	42.9 (0.2) 26	52.6 (2.3)	47.2 (2.1)	.109	.124
CDRS	29.4 (0.5) 16	34.6 (0.7) 18	28.6 (1.8)	30.1 (1.8)	.680	.993
PARS	13.3 (1.2) 23	15.8 (1.0) 25	12.0 (1.2)	13.4 (1.2)	.598	.283

Note: CDRS = Children’s Depression Rating Scale; CGAS = Children’s Global Assessment Severity; CGI = Clinical Global Impression; CTP = citalopram; MPH = methylphenidate; PARS = Pediatric Anxiety Rating Scale; PBO = placebo; SE = standard error.

Baseline descriptive statistics are based in observed data.

Descriptive statistics at week 8 of the trial and p values of differences in the randomized controlled trial are based on model-based estimates of the intent-to-treat analysis.

For CGI-I response, both estimated (n = 49) and observed (n = 41) data are provided.